Immunome Ownership | Who Owns Immunome?

Overview Forecast RevenueFinancials Chart

Immunome Ownership Summary

Immunome is owned by 35.65% institutional investors, 6.30% insiders, and 58.06% retail investors. Blackrock is the largest institutional shareholder, holding 36.46% of IMNM shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 5.74% of its assets in Immunome shares.

IMNM Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Immunome	35.65%	6.30%	58.06%
Sector	Healthcare Stocks	35.71%	11.88%	52.42%
Industry	Biotech Stocks	35.98%	11.86%	52.17%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	3.76M	36.46%	$45.48M
Fmr	16.97M	19.43%	$371.13M
T. rowe price investment management	16.36M	18.73%	$357.88M
Blackrock funding, inc. /de	8.17M	9.35%	$178.65M
Vanguard group	6.04M	6.87%	$129.71M
Redmile group	5.56M	6.36%	$121.57M
State street	5.40M	6.18%	$118.10M
Primecap management co/ca/	4.79M	5.48%	$104.72M
Wellington management group llp	4.73M	5.42%	$103.49M
Driehaus capital management	4.10M	4.69%	$89.66M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Enavate sciences gp	3.61M	22.48%	$79.03M
Redmile group	5.56M	8.05%	$121.57M
Pivotal bioventure partners investment advisor	732.51K	5.73%	$16.02M
Opaleye management	3.19M	5.27%	$37.30M
Silverarc capital management	1.85M	4.13%	$40.47M
Nan fung trinity (hk)	714.55K	1.72%	$15.63M
Sofinnova investments	1.70M	1.41%	$37.22M
Readystate asset management lp	1.30M	1.28%	$28.47M
Parkman healthcare partners	403.49K	0.91%	$8.82M
Atika capital management	262.90K	0.72%	$5.75M

Top Buyers

Holder	Shares	% Assets	Change
Wellington management group llp	4.73M	0.02%	3.80M
T. rowe price investment management	16.36M	0.25%	2.94M
Blackrock	3.76M	0.00%	2.93M
State street	5.40M	0.00%	1.53M
Vanguard group	6.04M	0.00%	1.14M

Top Sellers

Holder	Shares	% Assets	Change
Point72 asset management	-	-	-7.03M
Ecor1 capital	-	-	-2.86M
Citadel advisors	80.20K	0.00%	-1.66M
Balyasny asset management	251.40K	0.01%	-1.18M
Enavate sciences gp	3.61M	22.48%	-1.15M

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	716.39K	0.00%	716.39K	$15.67M
Toroso investments	275.90K	0.01%	275.90K	$6.03M
Axa investment managers	180.06K	0.01%	180.06K	$2.11M
Sio capital management	165.11K	0.52%	165.11K	$3.61M
Sphera funds management	147.20K	0.36%	147.20K	$1.72M

Sold Out

Holder	Change
Massmutual trust co fsb/adv	-5.00
Srs capital advisors	-19.00
Lindbrook capital	-38.00
Fny investment advisers	-50.00
Stephens consulting	-50.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	109	-44.10%	31,136,611	-73.69%	35	0.20%	59	-52.80%	27	-30.77%
Dec 31, 2025	109	-33.54%	43,416,568	-52.49%	49	0.45%	67	-27.96%	23	-37.84%
Sep 30, 2025	160	8.11%	91,368,868	15.03%	105	1.26%	91	7.06%	37	-
Jun 30, 2025	148	0.68%	79,432,018	9.01%	91	1.08%	85	-20.56%	37	105.56%
Mar 31, 2025	147	18.55%	76,924,342	44.29%	96	1.24%	108	54.29%	17	-51.43%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Growth Compy Commingled Pl S	6.50M	5.74%	309.78K
T. Rowe Price Small-Cap Stock	5.76M	5.10%	517.00K
T. Rowe Price US Small-Cap Core Equity	5.76M	5.10%	636.97K
Fidelity Growth Company Fund	4.74M	4.18%	228.20K
PRIMECAP Odyssey Aggressive Growth	3.87M	3.42%	53.00K
Fidelity Growth Compy Commingled Pl O	1.79M	2.97%	-
State Street® SPDR® S&P® Biotech ETF	3.27M	2.89%	-32.38K
Vanguard Total Stock Mkt Idx Inv	3.18M	2.81%	11.44K
T. Rowe Price Instl Small-Cap Stock	3.12M	2.76%	272.73K
T. Rowe Price U.S. SC Core Eq Tr-D	2.79M	2.47%	429.26K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 15, 2026	Rosett Max	Chief Financial Officer	Sell	$1.09M
Jun 05, 2026	BIENAIME JEAN JACQUES	-	Buy	$116.88K
Jun 05, 2026	BIENAIME JEAN JACQUES	-	Sell	$9.72K
Jun 05, 2026	BIENAIME JEAN JACQUES	-	Buy	$19.27K
Jun 05, 2026	BIENAIME JEAN JACQUES	-	Buy	$68.11K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	4	6
2026 Q1	3	2
2025 Q4	4	2
2025 Q3	-	-
2025 Q2	1	-

IMNM Ownership FAQ

Who Owns Immunome?

Immunome shareholders are primarily institutional investors at 35.65%, followed by 6.30% insiders and 58.05% retail investors. The average institutional ownership in Immunome's industry, Biotech Stocks , is 35.98%, which Immunome falls below.

Who owns the most shares of Immunome?

Immunome’s largest shareholders are Blackrock (3.76M shares, 36.46%), Fmr (16.97M shares, 19.43%), and T. rowe price investment management (16.36M shares, 18.73%). Together, they hold 74.62% of Immunome’s total shares outstanding.

Does Blackrock own Immunome?

Yes, BlackRock owns 36.46% of Immunome, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 45.48M$. In the last quarter, BlackRock increased its holdings by 2.93M shares, a 353.41% change.

Who is Immunome’s biggest shareholder by percentage of total assets invested?

Enavate sciences gp is Immunome’s biggest shareholder by percentage of total assets invested, with 22.48% of its assets in 3.61M Immunome shares, valued at 79.03M$.

Who is the top mutual fund holder of Immunome shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Immunome shares, with 5.74% of its total shares outstanding invested in 6.5M Immunome shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools